ACADIA Pharmaceuticals Inc (ACAD) - Cash Flow Conversion Efficiency
Based on the latest financial reports, ACADIA Pharmaceuticals Inc (ACAD) has a cash flow conversion efficiency ratio of 0.027x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($33.98 Million) by net assets ($1.25 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See ACAD equity financing ratio to measure how much of total assets are equity-financed.
ACADIA Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2002–2025)
This chart illustrates how ACADIA Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check ACAD cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.
ACADIA Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ACADIA Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Zhejiang Huahai Pharmaceutical Co Ltd
SHG:600521
|
0.029x |
|
Shanxi Coal International Energy Group Co Ltd
SHG:600546
|
0.134x |
|
Mirion Technologies Inc
NYSE:MIR
|
0.010x |
|
Yuhan Corp.
KO:000100
|
0.003x |
|
Huaihe Energy Group Co Ltd
SHG:600575
|
0.013x |
|
Edgewise Therapeutics Inc
NASDAQ:EWTX
|
-0.086x |
|
QL Resources Bhd
KLSE:7084
|
0.056x |
|
ENAGAS A.A. ADR1/2/EO150
F:EG40
|
0.014x |
Annual Cash Flow Conversion Efficiency for ACADIA Pharmaceuticals Inc (2002–2025)
The table below shows the annual cash flow conversion efficiency of ACADIA Pharmaceuticals Inc from 2002 to 2025. For the full company profile with market capitalisation and key ratios, see ACAD stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $1.23 Billion | $109.84 Million | 0.089x | -58.42% |
| 2024-12-31 | $732.79 Million | $157.72 Million | 0.215x | +456.38% |
| 2023-12-31 | $431.75 Million | $16.70 Million | 0.039x | +113.58% |
| 2022-12-31 | $400.41 Million | $-114.03 Million | -0.285x | -22.59% |
| 2021-12-31 | $540.89 Million | $-125.66 Million | -0.232x | -6.98% |
| 2020-12-31 | $627.01 Million | $-136.17 Million | -0.217x | -0.46% |
| 2019-12-31 | $699.13 Million | $-151.13 Million | -0.216x | +38.16% |
| 2018-12-31 | $479.08 Million | $-167.47 Million | -0.350x | +46.20% |
| 2017-12-31 | $335.29 Million | $-217.86 Million | -0.650x | -60.09% |
| 2016-12-31 | $518.41 Million | $-210.41 Million | -0.406x | +33.43% |
| 2015-12-31 | $199.76 Million | $-121.80 Million | -0.610x | -184.03% |
| 2014-12-31 | $309.49 Million | $-66.43 Million | -0.215x | -23.06% |
| 2013-12-31 | $182.13 Million | $-31.77 Million | -0.174x | +31.48% |
| 2012-12-31 | $84.98 Million | $-21.63 Million | -0.255x | +70.11% |
| 2011-12-31 | $23.36 Million | $-19.90 Million | -0.852x | -136.24% |
| 2010-12-31 | $29.69 Million | $-10.70 Million | -0.361x | +68.18% |
| 2009-12-31 | $12.11 Million | $-13.73 Million | -1.133x | +7.43% |
| 2008-12-31 | $52.99 Million | $-64.87 Million | -1.224x | -153.92% |
| 2007-12-31 | $113.93 Million | $-54.93 Million | -0.482x | +21.83% |
| 2006-12-31 | $67.16 Million | $-41.42 Million | -0.617x | -19.83% |
| 2005-12-31 | $39.37 Million | $-20.26 Million | -0.515x | +23.70% |
| 2004-12-31 | $30.68 Million | $-20.69 Million | -0.674x | -461.90% |
| 2003-12-31 | $-52.67 Million | $-9.82 Million | 0.186x | -19.17% |
| 2002-12-31 | $-40.09 Million | $-9.24 Million | 0.231x | -- |
About ACADIA Pharmaceuticals Inc
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America. The company offers NUPLAZID (pimavanserin), a selective serotonin inverse agonist/antagonist for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog … Read more